Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case reportReportar como inadecuado




Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Medical Case Reports

, 10:177

First Online: 16 June 2016Received: 16 December 2015Accepted: 30 May 2016DOI: 10.1186-s13256-016-0961-0

Cite this article as: Ueda, K., Suekane, S., Ogasawara, N. et al. J Med Case Reports 2016 10: 177. doi:10.1186-s13256-016-0961-0

Abstract

BackgroundMolecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. However, patients in whom the treatment could initially be effective will experience disease progression later.

Case presentationA 74-year-old Japanese man who was diagnosed with renal cell carcinoma with no evidence of metastasis presented to our hospital. He initially underwent radical nephrectomy, and subsequently the disease metastasized to the lung. Sorafenib was started for the lung metastases 1 year after the operation. The dose of sorafenib was reduced and temporarily discontinued because adverse events, including fatigue and cardiac infarction, occurred. The patient has continued sorafenib monotherapy for over 10 years without disease progression and severe adverse events.

ConclusionsWe present a rare case of a patient with metastatic renal cell carcinoma who has survived for over 10 years while receiving sorafenib monotherapy.

KeywordsRenal cell carcinoma Long-term response Sorafenib Monotherapy  Download fulltext PDF



Autor: Kosuke Ueda - Shigetaka Suekane - Naoyuki Ogasawara - Katsuaki Chikui - Shunsuke Suyama - Makoto Nakiri - Kiyoaki Nishihara

Fuente: https://link.springer.com/







Documentos relacionados